GNLX

SEC source: 0001209191-23-049519 · doc4.xml · nonDerivative · entry 1

Smither John W · CIK 0001559583 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,920

SEC source: 0001209191-23-049673 · doc4.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,135

F1 · price: The weighted average sale price for the transaction reported was $21.1385, and the range of prices were between $21.00 and $21.58. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-049587 · doc4.xml · nonDerivative · entry 2

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 60,568

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.665, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049587 · doc4.xml · nonDerivative · entry 1

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 63,883

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049349 · doc4.xml · nonDerivative · entry 4

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 79,600

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $22.14 to $23.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049349 · doc4.xml · nonDerivative · entry 3

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 93,327

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $21.1405 to $22.1245, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049099 · doc4.xml · derivative · entry 1

Cappello Joseph · CIK 0001939198 · VP, Pharmaceutical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-09-10

F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049105 · doc4.xml · derivative · entry 1

Ryder Sean · CIK 0001937485 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-09-10

F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049103 · doc4.xml · derivative · entry 1

Samuelson Doug · CIK 0001943326 · Vice President, Finance

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2033-09-10

F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049101 · doc4.xml · derivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2033-09-10

F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049096 · doc4.xml · derivative · entry 2

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,000

Underlying: Common Stock · 54,000 shares

Expires 2033-09-10

F2 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049096 · doc4.xml · nonDerivative · entry 1

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,065

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. 25% of the RSUs shall vest on June 1, 2024, and the remaining RSUs shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049095 · doc4.xml · derivative · entry 2

Jewett Caroline · CIK 0001983187 · Head of Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,000

Underlying: Common Stock · 88,000 shares

Expires 2033-09-10

F2 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049095 · doc4.xml · nonDerivative · entry 1

Jewett Caroline · CIK 0001983187 · Head of Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,135

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. 25% of the RSUs shall vest on June 30, 2024, and the remaining RSUs shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049093 · doc4.xml · derivative · entry 1

Zak Lourie S. · CIK 0001991207 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2033-09-10

F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049368 · doc4.xml · derivative · entry 2

Mirabelli Mary · CIK 0001937525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,397

Underlying: Common Stock · 4,397 shares

Expires 2033-09-10

F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-23-049368 · doc4.xml · nonDerivative · entry 1

Mirabelli Mary · CIK 0001937525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,460

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-23-049367 · doc4.xml · derivative · entry 2

Tyree James L · CIK 0001324991 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,397

Underlying: Common Stock · 4,397 shares

Expires 2033-09-10

F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-23-049367 · doc4.xml · nonDerivative · entry 1

Tyree James L · CIK 0001324991 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,460

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-23-049365 · doc4.xml · derivative · entry 2

Thomas John · CIK 0001939103 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,397

Underlying: Common Stock · 4,397 shares

Expires 2033-09-10

F2 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-23-049365 · doc4.xml · nonDerivative · entry 1

Thomas John · CIK 0001939103 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 482,460

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

SEC source: 0001209191-23-049364 · doc4.xml · derivative · entry 2

Smither John W · CIK 0001559583 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,447

Underlying: Common Stock · 8,447 shares

Expires 2033-09-10

F2 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over a three year period following the date of grant.

SEC source: 0001209191-23-049364 · doc4.xml · nonDerivative · entry 1

Smither John W · CIK 0001559583 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,820

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs shall vest in equal monthly installments over a three year period following the date of grant.

SEC source: 0001209191-23-049349 · doc4.xml · nonDerivative · entry 2

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 99,865

F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $22.02 to $22.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049349 · doc4.xml · nonDerivative · entry 1

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 122,885

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049675 · doc4.xml · derivative · entry 1

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2033-09-10

F1 · derivative.exercise_date: 25% of the shares shall vest on September 11, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001209191-23-049013 · doc4.xml · nonDerivative · entry 5

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 132,216

F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $24.165 to $24.205, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049013 · doc4.xml · nonDerivative · entry 4

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 134,852

F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $23.16 to $24.155, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049013 · doc4.xml · nonDerivative · entry 3

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 143,375

F4 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $22.16 to $23.1561, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049013 · doc4.xml · nonDerivative · entry 2

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 157,047

F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $25.03 to $25.55, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

SEC source: 0001209191-23-049013 · doc4.xml · nonDerivative · entry 1

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 159,555

F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $23.79 to $24.55, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

F2 · balance_after: The Form 3 filed by the reporting person on January 25, 2023 and the Form 4 filed by the reporting person on January 30, 2023 inadvertently overstated the amount of securities beneficially owned by one share.

SEC source: 0001209191-23-047784 · doc4.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,935

F1 · price: The weighted average sale price for the transaction reported was $24.70, and the range of prices were between $24.70 and $24.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-046883 · doc4.xml · nonDerivative · entry 1

Cappello Joseph · CIK 0001939198 · VP, Pharmaceutical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,735

F1 · shares: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-046890 · doc4.xml · nonDerivative · entry 1

Jewett Caroline · CIK 0001983187 · Head of Quality

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,135

F1 · shares: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-046887 · doc4.xml · nonDerivative · entry 1

Smalling Ralph · CIK 0001983288 · Head of Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,065

F1 · shares: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-046885 · doc4.xml · nonDerivative · entry 1

Samuelson Doug · CIK 0001943326 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,303

F1 · shares: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-046884 · doc4.xml · nonDerivative · entry 1

Ryder Sean · CIK 0001937485 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 572

F1 · shares: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-046879 · doc4.xml · nonDerivative · entry 1

Yu Yong · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,735

F1 · shares: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-046877 · doc4.xml · nonDerivative · entry 1

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,651

F1 · shares: Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $23.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001209191-23-026505 · doc4.xml · nonDerivative · entry 1

Zindrick Thomas · CIK 0001937573 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,000

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-026483 · doc4.xml · nonDerivative · entry 1

Cappello Joseph · CIK 0001939198 · VP, Pharmaceutical Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-026524 · doc4.xml · nonDerivative · entry 1

Tyree James L · CIK 0001324991 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-026517 · doc4.xml · nonDerivative · entry 1

Mirabelli Mary · CIK 0001937525 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-026511 · doc4.xml · nonDerivative · entry 1

Woodward Gabe · CIK 0001938448 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,186

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-026507 · doc4.xml · nonDerivative · entry 1

Thomas John · CIK 0001939103 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 479,000

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-026501 · doc4.xml · nonDerivative · entry 1

Zhang Qian · CIK 0001937484 · Associate VP, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,333

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-026497 · doc4.xml · nonDerivative · entry 1

Ryder Sean · CIK 0001937485 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 900

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-026491 · doc4.xml · nonDerivative · entry 1

Samuelson Doug · CIK 0001943326 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,600

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-026488 · doc4.xml · nonDerivative · entry 1

Yu Tony · CIK 0001937482 · VP, Clinical Trial Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,000

F1 · kind: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will be fully vested on July 25, 2023.

SEC source: 0001209191-23-005480 · doc4.xml · derivative · entry 7

Szalay Aladar · CIK 0001937513 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 0

Underlying: Common Stock · 500,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock at a conversion ratio of 1 share of Common Stock for each 3 shares of Preferred Stock upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F1 · price: Each share of Series A Preferred Stock automatically converted into shares of Common Stock at a conversion ratio of 1 share of Common Stock for each 3 shares of Preferred Stock upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock at a conversion ratio of 1 share of Common Stock for each 3 shares of Preferred Stock upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Preferred Stock automatically converted into shares of Common Stock at a conversion ratio of 1 share of Common Stock for each 3 shares of Preferred Stock upon the closing of the Issuer's initial public offering. The Series A Preferred Stock had no expiration date.

F3 · ownership.nature: Shares held by The Szalay Children's Trust.